BIODESIX, INC. (BDSX) Operating Margin
- Operating margin · 12 months: Value -20.02%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -20.02% | Operating income / revenue. Period ending 2026-06-30. $-20.61M ÷ $102.94M × 100 ≈ -20.02% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -20.61M USD | Operating Income (Loss) |
| Revenue | 102.94M USD | |
| Cost of products and services | (m) | |
| Research and development | 12.28M USD | Research and Development Expense |
| Selling, general and administration | 93.23M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-20.61M | $102.94M | (m) | $12.28M | $93.23M | -20.02% |
| 2026-03-31 | $-24.94M | $96.10M | (m) | $12.42M | $91.36M | -25.95% |
| 2025-12-31 | $-27.87M | $88.50M | (m) | $12.00M | $87.55M | -31.50% |
| 2025-09-30 | $-32.55M | $80.17M | (m) | $11.54M | $84.79M | -40.61% |
| 2025-06-30 | $-34.09M | $76.56M | (m) | $11.10M | $83.09M | -44.54% |
| 2025-03-31 | $-32.61M | $74.46M | (m) | $10.39M | $80.34M | -43.80% |
| 2024-12-31 | $-34.50M | $71.32M | (m) | $9.56M | $80.45M | -48.37% |
| 2024-09-30 | $-34.72M | $65.56M | (m) | $9.03M | $76.48M | -52.96% |
| 2024-06-30 | $-33.30M | $60.90M | (m) | $8.43M | $71.96M | -54.68% |
| 2024-03-31 | $-35.99M | $54.85M | (m) | $8.78M | $68.95M | -65.62% |
| 2023-12-31 | $-41.34M | $49.09M | (m) | $9.99M | $67.39M | -84.22% |
| 2023-09-30 | $-48.36M | $44.03M | (m) | $11.66M | $67.76M | -109.85% |
| 2023-06-30 | $-51.80M | $41.64M | (m) | $12.70M | $67.38M | -124.39% |
| 2023-03-31 | $-52.50M | $40.72M | (m) | $13.15M | $65.96M | -128.93% |
| 2022-12-31 | $-50.59M | $38.21M | (m) | $13.10M | $61.46M | -132.39% |
| 2022-09-30 | $-48.38M | $35.83M | (m) | $12.39M | $58.39M | -135.02% |
| 2022-06-30 | $-50.86M | $31.25M | (m) | $12.71M | $56.89M | -162.73% |
| 2022-03-31 | $-49.82M | $32.19M | (m) | $12.67M | $53.08M | -154.77% |
| 2021-12-31 | $-40.94M | $54.51M | (m) | $12.79M | $50.52M | -75.11% |
| 2021-09-30 | $-31.91M | $74.31M | (m) | $13.04M | $49.02M | -42.95% |
| 2021-06-30 | $-25.06M | $76.97M | (m) | $12.46M | $43.30M | -32.56% |
| 2021-03-31 | $-20.09M | $69.33M | (m) | $11.24M | $38.70M | -28.99% |
| 2020-12-31 | $-22.93M | $45.56M | (m) | $10.82M | $34.86M | -50.34% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-26.74M | $24.55M | (m) | $10.47M | $30.64M | -108.92% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |